Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

US giant, Eli Lilly launched Mounjaro (tirzepatide) which is a prescription medicine for adults with type 2 diabetes used ...

Following in the footsteps of blockbuster drugs such as Ozempic and Wegovy—both powered by semaglutide—Mounjaro (approved for ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India following approval from the country's drug ...

Pharma giant Eli Lilly has launched Mounjaro, a popular weight-loss drug, in India. Priced at Rs 3,500 for 2.5 mg and Rs 4,375 for 5 mg, Mounjaro is a ...

US pharma giant Eli Lilly has ventured into India with an anti-obesity and diabetes drug called Mounjaro. This development ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India, marking its entry into a rapidly growing market.

Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...

Rajya Sabha member Milind Deora has criticised the launch of Mounjaro in India. The weight-loss drug, developed by US-based ...

Eli Lilly has launched Mounjaro in India, a groundbreaking weight loss and diabetes drug, at a fraction of its US price. The ...

Eli Lilly’s Mounjaro has launched in India. Approved by CDSCO, it promises significant weight loss and blood sugar control. However, concerns remain over certain side effects.

While experts welcomed Mounjaro's launch, they stressed the importance of responsible prescribing to prevent misuse of the drug used for the treatment of type 2 diabetes and obesity.